Zobrazeno 21 - 30
of 181
pro vyhledávání: ''
Autor:
Charles Havnar, Daniel Oreper, Katrina Krogh, Richard Bourgon, Oliver A. Zill, Nicolas W. Lounsbury, Amy C. Y. Lo, Thomas D. Wu, Ryan Jones, Ximo Pechuan-Jorge, Guang Yu Yang, Andrew J Wallace
Publikováno v:
Journal for Immunotherapy of Cancer
Journal for ImmunoTherapy of Cancer, Vol 9, Iss 10 (2021)
Journal for ImmunoTherapy of Cancer, Vol 9, Iss 10 (2021)
BackgroundIndividualized neoantigen-specific immunotherapy (iNeST) requires robustly expressed clonal neoantigens for efficacy, but tumor mutational heterogeneity, loss of neoantigen expression, and variable tissue sampling present challenges. It is
Autor:
Koichiro Higasa, Naho Atsumi, Tadashi Matsuda, Takashi Yoshida, Junichi Ikeda, Ryoichi Saito, Haruyuki Ohsugi, Motohiko Sugi, Koji Tsuta, Chisato Ohe, Hidefumi Kinoshita
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 9, Iss 9 (2021)
Journal for Immunotherapy of Cancer
Journal for Immunotherapy of Cancer
BackgroundClear cell renal cell carcinoma (ccRCC) displays heterogeneity in appearance—a distinctive pale clear to eosinophilic cytoplasm; however, little is known about the underlying mechanisms and clinical implications. We investigated the role
Publikováno v:
Journal for Immunotherapy of Cancer
Journal for ImmunoTherapy of Cancer, Vol 9, Iss 9 (2021)
Journal for ImmunoTherapy of Cancer, Vol 9, Iss 9 (2021)
Immune checkpoint inhibitors (ICIs) have revolutionized cancer therapy but can result in toxicities, known as immune-related adverse events (irAEs), due to a hyperactivated immune system. ICI-related inflammatory arthritis has been described in liter
Autor:
Kim Minju, Sung-Han Kim, Yong Pil Chong, Jiwon Jung, Min Jae Kim, Jwa Hoon Kim, Seongman Bae, Yang Soo Kim, Sang-Ho Choi, Sang-Oh Lee, Sung-Cheol Yun, Ye-Jee Kim
Publikováno v:
Journal for Immunotherapy of Cancer
Journal for ImmunoTherapy of Cancer, Vol 9, Iss 9 (2021)
Journal for ImmunoTherapy of Cancer, Vol 9, Iss 9 (2021)
BackgroundWhile some recent studies have reported the development of tuberculosis (TB) in patients exposed to immune checkpoint inhibitors (ICIs), there is limited evidence to date. Therefore, we evaluated the risk of TB in patients with cancer expos
Autor:
Eirini Pectasides, Sarah Derks, Charles S. Fuchs, Megan E. Cavanaugh, Peter C. Enzinger, Anuj K. Patel, Amanda J. Rode, Douglas A. Rubinson, Adam J. Bass, Bridget Fitzpatrick, Lauren K. Brais, Nadine Jackson McCleary, Mariano Severgnini, Patrick H. Lizotte, Fahire G Akarca, Jeffrey W. Clark, Leonie K. de Klerk, Melissa G Jean, Matthew Nazzaro, Jeremy Augustin, Mohamed Uduman, James M. Cleary, Hui Zheng, Nihal Raman
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 9, Iss 9 (2021)
Journal for Immunotherapy of Cancer, 9(9):e002472. BioMed Central
de Klerk, L K, Patel, A K, Derks, S, Pectasides, E, Augustin, J, Uduman, M, Raman, N, Akarca, F G, McCleary, N J, Cleary, J M, Rubinson, D A, Clark, J W, Fitzpatrick, B, Brais, L K, Cavanaugh, M E, Rode, A J, Jean, M G, Lizotte, P H, Nazzaro, M J, Severgnini, M, Zheng, H, Fuchs, C S, Enzinger, P C & Bass, A J 2021, ' Phase II study of pembrolizumab in refractory esophageal cancer with correlates of response and survival ', Journal for Immunotherapy of Cancer, vol. 9, no. 9, e002472 . https://doi.org/10.1136/jitc-2021-002472, https://doi.org/10.1136/jitc-2021-002472
Journal for Immunotherapy of Cancer
Journal for Immunotherapy of Cancer, 9(9):e002472. BioMed Central
de Klerk, L K, Patel, A K, Derks, S, Pectasides, E, Augustin, J, Uduman, M, Raman, N, Akarca, F G, McCleary, N J, Cleary, J M, Rubinson, D A, Clark, J W, Fitzpatrick, B, Brais, L K, Cavanaugh, M E, Rode, A J, Jean, M G, Lizotte, P H, Nazzaro, M J, Severgnini, M, Zheng, H, Fuchs, C S, Enzinger, P C & Bass, A J 2021, ' Phase II study of pembrolizumab in refractory esophageal cancer with correlates of response and survival ', Journal for Immunotherapy of Cancer, vol. 9, no. 9, e002472 . https://doi.org/10.1136/jitc-2021-002472, https://doi.org/10.1136/jitc-2021-002472
Journal for Immunotherapy of Cancer
BackgroundImmune checkpoint inhibitors have revolutionized cancer treatment, but the benefits in refractory patients with esophageal cancer have been modest. Predictors of response as well as new targets for novel therapeutic combinations are needed.
Autor:
Andrew F. Hill, Victoria Atkinson, Vanna Chiarion-Sileni, Jeffrey S. Weber, Nikhil I. Khushalani, Leslie A. Fecher, Anna Maria Di Giacomo, Michael Schenker, James E. Larkin, Marcus O. Butler, Petr Arenberger, Helen Gogas, Ana Arance, Maurice Lobo, Luis de la Cruz-Merino, Jose Lutzky, C. Lance Cowey, Stéphane Dalle, Veerle de Pril, Jean-Jacques Grob, Ivan Marquez-Rodas, Mario Mandalà, Paolo A. Ascierto, Michele Del Vecchio, Michael Millward
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 9, Iss 8 (2021)
Journal for Immunotherapy of Cancer
Journal for Immunotherapy of Cancer
BackgroundSeveral therapeutic options are now available in the adjuvant melanoma setting, mandating an understanding of their benefit‒risk profiles in order to make informed treatment decisions. Herein we characterize adjuvant nivolumab select (imm
Autor:
Andreanne M. Lacroix, Steven P. Fling, Lawrence Fong, Chihiro Morishima, Frederick Millard, Nirasha Ramchurren, Russell K. Pachynski, Martin A. Cheever, Anne Gregoire, Lauren C. Harshman, Paul Monk, Omer Kucuk, Leonard A D'Amico, Leonard Joseph Appleman, Michel Morre, John D. Seigne, Caroline Duault, Judith C Kaiser, Russell Z. Szmulewitz, Evan Y. Yu, Bruce W. Hess, Rhonda L. Bitting, Holden T. Maecker
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 9, Iss 8 (2021)
Journal for immunotherapy of cancer, vol 9, iss 8
Journal for Immunotherapy of Cancer
Journal for immunotherapy of cancer, vol 9, iss 8
Journal for Immunotherapy of Cancer
BackgroundSipuleucel-T (sip-T) is a Food and Drug Administration (FDA)-approved autologous cellular immunotherapy for metastatic castration-resistant prostate cancer (mCRPC). We hypothesized that combining sip-T with interleukin (IL)-7, a homeostatic
Autor:
Tanya B. Dorff, Jared David Acoba, Yosuke Hirasawa, Hideki Furuya, Mark Scholz, Minlu Zhang, Charles J. Rosser, John Shon, Jeffrey Huang, Winston A. Haynes, David Jon Tamura, Sumanta K. Pal, Abhilash Dhal, Rebecca Waitz, Owen T. M. Chan, Ian Pagano
Publikováno v:
Journal for Immunotherapy of Cancer
Journal for ImmunoTherapy of Cancer, Vol 9, Iss 8 (2021)
Journal for ImmunoTherapy of Cancer, Vol 9, Iss 8 (2021)
BackgroundCombining an immune checkpoint inhibitor with a tumor vaccine may modulate the immune system to leverage complementary mechanisms of action that lead to sustained T-cell activation and a potent prolonged immunotherapeutic response in metast
Autor:
Eleanor Y. Chen, Bonnie LaFleur, Jose G. Mantilla, Brett Schroeder, Marissa Vignali, Shihong Zhang, Seth M. Pollack, Michael J. Wagner, Laura Riolobos, Brian C Schulte, Robert H. Pierce, Kevin C Flanagan, Kimberly S. Smythe, Julie Rytlewski, Lee D. Cranmer, Robin L. Jones, Natalie A. LaFranzo, Teresa S. Kim, Jean S. Campbell, Rachel M. Gittelman
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 9, Iss 8 (2021)
Journal for Immunotherapy of Cancer
Journal for Immunotherapy of Cancer
BackgroundDedifferentiated liposarcoma (DDLPS) is one of the most common soft tissue sarcoma subtypes and is devastating in the advanced/metastatic stage. Despite the observation of clinical responses to PD-1 inhibitors, little is known about the imm
Autor:
Alexia Iasonos, Roisin E. O'Cearbhaill, Qin Zhou, Ekaterina Doubrovina, David R. Spriggs, Carol Aghajanian, Sara Kravetz, Richard J. O'Reilly, Paul Sabbatini, Chrisann Kyi
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 9, Iss 8 (2021)
Journal for Immunotherapy of Cancer
Journal for Immunotherapy of Cancer
BackgroundThis phase I dose escalation trial evaluated the feasibility of production, safety, maximum tolerated dose, and preliminary efficacy of autologous T cells sensitized with peptides encoding Wilms’ tumor protein 1 (WT1) administered alone o